Emerging Treatments | Major Lung Disorders - 2025 World Medical Innovation Forum

Disorders of the pulmonary system such as idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH), interstitial lung disease (ILD), COPD, and bronchiectasis exhibit high morbidity and mortality for which global incidence is increasing. This panel will discuss the current approaches to treating these diseases and will discuss prospects for therapeutics that are currently in the pipelines of pharma companies especially those currently in clinical trials. Drug classes to be discussed will include activin signaling inhibitors (e.g. Merck’s Winrevair), phosphodiesterase (PDE) inhibitors, prostacyclins, and more.

Moderators

Jason Gerberry,

Specialty Pharma and SMId-Cap Biotech Analyst, BofA Securities

Jason Zemansky,

SMid-Cap Biotech Analyst, BofA Securities

Speakers

Craig Hersh, MD,

Physician, Channing Division of Network Medicine, Brigham and Women’s Hospital;

Associate Professor of Medicine, Harvard Medical School

Bruce Levy, MD

Executive Vice Chair, Department of Medicine, Mass General Brigham;

Hersey Professor of the Theory and Practice of Physic, Harvard Medical School

Aaron Waxman, MD, PhD,

Executive Director, Center for Pulmonary Heart Disease, Brigham and Women’s Hospital;

Associate Professor of Medicine, Harvard Medical School

Search Our Site

Emerging Treatments | Major Lung Disorders

Picasso Ballroom